MetaVia
MTVA · Nasdaq · United States
Share price · MTVA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MTVA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026-15.2%
- 6 Nov 2026+31.2%
- 5 Nov 2026-18.7%
- 27 Oct 2026-5.3%
Nothing announced by MTVA that day or the session before.
- 26 Oct 2026-12.0%
Nothing announced by MTVA that day or the session before.
- 8 Oct 2026-8.2%
Nothing announced by MTVA that day or the session before.
- 18 Sep 2026+8.8%
Nothing announced by MTVA that day or the session before.
- 22 May 2026+34.1%
Nothing announced by MTVA that day or the session before.
- 20 May 2026+53.7%
- 19 May 2026+69.4%
Share of unusual movement by asset
For each asset, the share of MTVA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | GPR119Small molecule | Type 2 DiabetesMASH / NASH | |
| Phase 1 | GLP-1/glucagon receptor (dual)Peptide | Obesity |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $2.6M | $8.8M | $4.6M-$3.7M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | — | $13M | $5.3M-$3.8M operating cash flow | report ↗ |
| 2026-Q1 | — | — | $14M | $3.8M-$4.3M operating cash flow | report ↗ |
| 2025-Q3 | — | — | $14M | $3.4M-$3.0M operating cash flow | report ↗ |
| 2025-Q2 | — | — | $18M | $4.0M-$3.1M operating cash flow | report ↗ |
| 2025-Q1 | — | $2.3M | $11M | $3.7M-$4.8M operating cash flow | report ↗ |
| 2024-Q3 | — | $4.5M | $22M | $5.7M-$5.6M operating cash flow | report ↗ |
| 2024-Q2 | — | $8.1M | $28M | $10M-$7.3M operating cash flow | report ↗ |
| 2024-Q1 | — | $4.9M | $16M | $6.7M-$6.4M operating cash flow | report ↗ |
| 2023-Q3 | — | $2.3M | $26M | $3.8M-$2.8M operating cash flow | report ↗ |
| 2023-Q2 | — | $2.4M | $29M | $0.7M-$2.0M operating cash flow | report ↗ |
| 2023-Q1 | — | $0.6M | $31M | $2.6M-$2.5M operating cash flow | report ↗ |
| 2022-Q3 | — | $0.6M | $6.4M | $3.1M-$2.4M operating cash flow | report ↗ |
| 2022-Q2 | — | $1.0M | $8.8M | $3.3M-$2.7M operating cash flow | report ↗ |
| 2022-Q1 | — | $0.9M | $12M | $2.9M-$4.8M operating cash flow | report ↗ |
| 2021-Q3 | — | $1.4M | $7.0M | $3.5M-$2.5M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | — | $10M | $3.2M-$16M operating cash flow | report ↗ |
MetaVia reported a net loss of $13.0 million for the full year 2025, compared with a net loss of $27.6 million in 2024. R&D expenses were approximately $6.8 million, down approximately $14.8 million YoY, while cash and cash equivalents totaled $10.3 million as of December 31, 2025, versus $16.0 million at year-end 2024. Revenue was not disclosed.
MetaVia guided that its existing cash, together with gross proceeds of approximately $9.3 million from a January 2026 public offering, is expected to fund operations into the fourth quarter of 2026. Positive Phase 1 data for DA-1726 showed 9.1% weight loss with improved glucose control and liver benefit, and the company plans to initiate Phase 1 Part 3 titration studies in April 2026 with data expected in the fourth quarter. It also presented positive Phase 2a data for vanoglipel (DA-1241) in MASH at AASLD and is working to schedule an end-of-Phase 2 meeting with the FDA.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-12 | Browne Sarah Kaplan · Chief Medical Officer | Award / grant | 53,000 | — | — | Form 4 |
| 2026-06-08 | Glickman Mark A · director | Award / grant | 17,186 | — | — | Form 4 |
| 2026-06-08 | KOVEN ANDREW I · director | Award / grant | 17,186 | — | — | Form 4 |
| 2026-06-08 | GROVES JASON L · director | Award / grant | 17,186 | — | — | Form 4 |
| 2026-06-08 | Salsbury Michael · director | Award / grant | 17,186 | — | — | Form 4 |
| 2026-06-08 | STRICKLAND D GORDON · director | Award / grant | 17,186 | — | — | Form 4 |
| 2026-06-08 | Tursi James Patrick · director | Award / grant | 17,186 | — | — | Form 4 |
| 2026-01-23 | Kim Hyung Heon · director, CEO & President | Award / grant | 32,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 12 reporting institutions held 0.1M shares ($80K, 1.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 33,635 | $40K |
| 2 | JANE STREET GROUP, LLC | 10,903 | $13K |
| 3 | Aries Wealth Management | 10,000 | $12K |
| 4 | VANGUARD FIDUCIARY TRUST CO | 6,940 | $8K |
| 5 | Tower Research Capital LLC (TRC) | 2,602 | $3K |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2,222 | $3K |
| 7 | BlackRock, Inc. | 479 | $575 |
| 8 | SBI Securities Co., Ltd. | 205 | $246 |
| 9 | Caitong International Asset Management Co., Ltd | 3 | $4 |
| 10 | BROWN BROTHERS HARRIMAN & CO | 2 | $2 |
| 11 | DANSKE BANK A/S | 2 | $2 |
| 12 | UBS Group AG | 1 | $1 |